A5058536201- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Effects of Radiation Exposure
- CNS Lymphoma Diagnosis and Treatment
- Ocular Oncology and Treatments
- DNA Repair Mechanisms
- Retinoids in leukemia and cellular processes
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- RNA Interference and Gene Delivery
- Robotics and Automated Systems
- Cancer, Stress, Anesthesia, and Immune Response
- Brain Tumor Detection and Classification
- Advanced Electron Microscopy Techniques and Applications
- Central Venous Catheters and Hemodialysis
- Nanoplatforms for cancer theranostics
- Mathematical Biology Tumor Growth
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Meningioma and schwannoma management
- Olfactory and Sensory Function Studies
- Spine and Intervertebral Disc Pathology
Nanjing Forestry University
2024
Weatherford College
2024
Johns Hopkins Medicine
2009-2018
Johns Hopkins University
2009-2018
Sidney Kimmel Comprehensive Cancer Center
2010-2014
Massachusetts General Hospital
2010-2013
Saitama Medical University
2013
The University of Texas MD Anderson Cancer Center
2013
Dana-Farber Cancer Institute
2013
University of Utah
2012
Mammals can perceive and discriminate myriad volatile chemicals as having a distinct odor. Odorants are initially detected by odorant receptors (ORs) on olfactory sensory neurons (OSNs) in the nose. In mouse, each OSN expresses one of ∼1000 different OR genes. Although OSNs their expressed ORs constitute fundamental units input to brain, comprehensive understanding how they encode odor identities is still lacking. To gain broader more detailed recognition coding at this level, we tested...
A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma,
The objectives of this study were to determine the safety and efficacy polyinosinic-polycytidylic acid stabilized with poly-l-lysine carboxymethylcellulose (poly-ICLC) when added radiation temozolomide (TMZ) in adults newly diagnosed glioblastoma (GB). Patients received external beam concurrent TMZ (75 mg/m2/day) followed by adjuvant (150–200 mg/m2/day for 5 consecutive days once every 9 weeks) intramuscular poly-ICLC (20 mg/kg/dose given 3× per week weeks 2–8). An cycle was operationally...
2001 Background: EMD 121974 (cilengitide) is a selective integrin receptor inhibitor that well tolerated and has demonstrated biological activity in patients with malignant glioma. The objectives of this phase II trial were to determine safety when combined chemoradiation estimate the overall survival for two different doses newly diagnosed GBM. Methods: A total 112 accrued onto through NABTT CNS consortium. Cilengitide was administered by one-hour infusion twice week 18 treated run-in 6 at...
2010 Background: R-(-)-gossypol (AT-101) is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-X L , Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins. A prior study racemic gossypol demonstrated objective responses in patients with malignant glioma. The objectives this trial were to determine the efficacy safety more active (-) enantiomer recurrent GBM. Methods: Fifty-six GBM enrolled multi-institution phase II clinical through NABTT CNS consortium designed detect a 33% increase...
2012 Background: TMZ and radiotherapy (RT) improve survival in patients with glioblastoma multiforme. However, DNA repair mechanisms confer resistance to these therapies. Inhibition of PARP1, a critical enzyme, enhances activity glioma models. This study seeks define the optimal dose PARP inhibitor BSI-201 given newly diagnosed malignant (MG). Methods: Eligibility: MG; ≥18 yrs; received ≥80% planned RT concurrent without grade 3/4 toxicity. Patients either 75 mg/m2 qd biweekly for 6 wks or...
2003 Background: Many novel agents are being studied in combination with radiation and temozolomide (RT+TMZ) newly diagnosed glioblastoma using survival as the primary endpoint. These single arm phase II studies generally plan to compare their results those reported from III EORTC RT+TMZ study (Stupp, NEJM, 2005). Methods: The NABTT CNS Consortium has completed accrual three RT+TMZ+ agent same eligibility criteria. A total of 281 patients were enrolled. included talampanel (72 pts), poly...
11 Background: Pomegranate extract (POMx) demonstrates promising antitumor effects in prostate cancer (PCA). Prior published work reveals an increase PSA doubling time (PSADT) a single arm study of pomegranate juice (POM) PCA patients (pts) with rising after local therapy. We sought to determine the low (1 gram) or high (3 grams) daily POMx on PSADT similar but broader population men seeking defer androgen deprivation Methods: Our multi-center, double bind phase II trial randomized and...
BACKGROUND: The treatment of patients with primary CNS lymphomas (PCNSL) has dramatically changed since the 1970's when whole brain radiation generated median survivals about 12 months, significant neurotoxcity, and few long term survivors.High dose methotrexate (HD-MTX) monotherapy without provides excellent response rates 30% survivors neurotoxicity.In general, relapses occur in first two to four years after diagnosis reports very late are rare.METHODS: Charts all treated HD-MTX for newly...
This study aimed to assess hematological diseases next-generation sequencing (NGS) panel enhances the diagnosis and classification of myeloid neoplasms (MN) using 5th edition WHO Classification Hematolymphoid Tumors (WHO-HAEM5) International Consensus (ICC) Myeloid Tumors. A cohort 112 patients diagnosed with MN according revised fourth (WHO-HAEM4R) underwent testing a 141-gene NGS for diseases. Ancillary studies were also conducted, including bone marrow cytomorphology routine cytogenetics....
Nuclear export factor chromosome region maintenance 1 (CRM1) mediated the transport of various growth-regulatory proteins and was frequently overexpressed in many hematologic solid tumors. Selinexor (KPT-330) only approved CRM1 inhibitor, but severe gastrointestinal central nervous system toxicities limited its clinical application. In this manuscript, a series novel second-generation inhibitors were designed, which
Characterizing graph neural networks (GNNs) is essential for identifying performance bottlenecks and facilitating their deployment. Despite substantial work in this area, a comprehensive survey on GNN characterization lacking. This presents survey, proposing triple-level classification method to categorize, summarize, compare existing efforts. In addition, we identify promising future directions characterization. Our aims help scholars systematically understand patterns from computer...
1570 Background: NABTT opened trial 2105 to determine the maximum tolerated dose (MTD) of GliaSite Brachytherapy (GSBT) with external beam radiation therapy (EBRT) in treatment newly-diagnosed GBM (NDGBM). Methods: Patients were enrolled cohorts 5 and received postoperative GSBT followed by conventional EBRT 46 Gy +14 boost. began within 30 days after GSBT, but not more than 60 post surgery. A DLT was defined as CTC 2.0 grade 3/4 toxicity resolved 1 month onset or 3 months from end...
2002 Background: Polyinosinic-polycytidylic (poly-ICLC), is a double-stranded RNA that stimulates variety of host defense mechanisms including T-cell and natural killer cell activation, cytokine release specific anti-proliferative anti-viral effects. The objective this study was to determine the safety efficacy poly-ICLC when added adjuvant treatment for newly diagnosed glioblastoma. Methods: Newly patients > 18 years with histologically proven glioblastoma received standard external beam...
1538 Background: Significant tumor control and prolongation of survival have been demonstrated by combined use radiosurgery antivascular agent, Arsenic Trioxide (ATO), in rodent gliosarcoma model rats. This agent is now undergoing clinical evaluation the NABTT Brain Tumor Consortium a Phase I trial with ATO dose escalation combination fractionated radiation therapy. Since this showed rapid effect on vasculature animal studies, MRI perfusion diffusion studies were performed shortly following...
BACKGROUND: For many years, patients with anaplastic oligodendrogliomas (AO) have been treated radiation and temozolomide followed by adjuvant (RT/TMZ). Two randomized studies, RTOG 9402 EORTC 26951 recently showed significantly improved survival in 1p/19q co-deleted AO plus PCV (RT/PCV) versus alone. A controlled study comparing RT/PCV RT/TMZ is underway, but obtaining definitive answers takes long as are rare long. Our goal was to assess the feasibility of a retrospective analysis compare...
BACKGROUND: Addition of temozolomide (TMZ) to standard radiation has become common clinical practice in patients with anaplastic astrocytoma (AA). Prospective trials will ultimately inform its utility but results not be available for years. Three retrospective studies have questioned whether TMZ improves survival over alone methodologic limitations their conclusions. OBJECTIVE: To determine trends AA prior and following the inclusion into practice. METHODS: A single-institution study was...